Nitric Oxide to Treat Pulmonary Embolism
Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism
Sponsor: Indiana University School of Medicine
Listed as NCT01939301, this PHASE2 trial focuses on Pulmonary Embolism and remains completed. Sponsored by Indiana University School of Medicine, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Indiana University School of Medicine
- Mallinckrodt
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health (NIH)
- University of Mississippi Medical Center
- University of Texas, Southwestern Medical Center at Dallas
For direct contact, visit the study record on ClinicalTrials.gov .